The influence of beam energy on the outcome of postoperative radiotherapy in head and neck cancer patients: secondary analysis of RTOG 85-03.

A. Aref,B. Berkey,J. Schwade,J. Ensley,D. Schuller,R. Haselow,T. Ervin,G. Laramore

DOI: https://doi.org/10.1016/S0360-3016(00)00457-0

Abstract:

What problem does this paper attempt to address?

Comprehensive Investigation of Mutational Features of Various Lung Adenocarcinoma Histological Subtypes among Chinese Patients.

C. Xiang,Y. Han,H. Teng,L. Zhu,J. Shao,J. Zhao,S. Ma,J. Lin,J. Zheng,A. Lizaso

DOI: https://doi.org/10.1200/jco.2020.38.15_suppl.e21090

IF: 45.3

2020-01-01

Journal of Clinical Oncology

Abstract:e21090 Background: Lung adenocarcinoma (LUAD) is further classified into several histological subtypes according to the World Health Organization classification; however, data on the molecular profile of these histological subtypes are limited. In this study, we aimed to investigate the mutational features of various LUAD histological subtypes among Chinese patients. Methods: We retrospectively analyzed clinical, histopathologic, and sequencing data from 3,425 consecutive patients diagnosed with stage IA-IVB LUAD between January 2017 to December 2019 at the Department of Pathology. Results: Based on histologic subtype, the cohort comprised of 0.2% atypical adenomatous hyperplasia (AAH, n = 6), 7.2% adenocarcinoma in situ (AIS, n = 246), 14.0% minimally invasive adenocarcinoma (MIA, n = 479), and 78.6% invasive adenocarcinoma (INV, n = 2,694), including 42.0% acinar (n = 1,438), 12.7% papillary (n = 435), 8.8% lepidic (n = 302), 8.5% solid (n = 290), 3.2% micropapillary (n = 109), 2.8% invasive mucinous (n = 95), 0.6% enteric (n = 21), 0.1% fetal (n = 3), and 0.1% colloid (n = 1). Analysis of mutation profiles revealed significantly higher mutation detection rates of ERBB2 ( P< 0.01), BRAF ( P< 0.01), and MAP2K1 ( P= < 0.01) among patients with AIS, AAH and MIA as compared to patients with INV. Meanwhile, TP53 ( P< 0.01) and EGFR ( P< 0.01) mutations were significantly higher among patients with INV as compared to patients with AIS and MIA. Among the invasive subtypes, patients with invasive mucinous adenocarcinoma had significantly higher KRAS mutation rate (75%, P< 0.01). Lepidic (81%), acinar (80%), papillary (77%), and micropapillary (66%) were the subtypes with the highest EGFR mutation rates. Conclusions: By analyzing the genomic data of a large cohort of patients, our study provides a more comprehensive outlook of gene mutations according to LUAD histological subtypes. Enrichement of actionable mutation in particular histological subtype contributes to more treatment option and better clinical outcomes as compared to other histological subtype, indicating the clinical relevance of performing comprehensive mutation profiling in addition to histopathologic analysis in all LUAD patients.
Oncogenic Mutations Are Associated with Histological Subtypes but Do Not Have an Independent Prognostic Value in Lung Adenocarcinoma

Haichuan Hu,Yunjian Pan,Yuan Li,Lei Wang,Rui Wang,Yang Zhang,Hang Li,Ting Ye,Yiliang Zhang,Xiaoyang Luo,Longlong Shao,Zhengliang Sun,Deng Cai,Jie Xu,Qiong Lu,Youjia Deng,Lei Shen,Hongbin Ji,Yihua Sun,Haiquan Chen

DOI: https://doi.org/10.2147/ott.s58900

IF: 4

2014-01-01

OncoTargets and Therapy

Abstract:Lung adenocarcinomas have diverse genetic and morphological backgrounds and are usually classified according to their distinct oncogenic mutations (or so-called driver mutations) and histological subtypes (the de novo classification proposed by the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society [IASLC/ATS/ERS]). Although both these classifications are essential for personalized treatment, their integrated clinical effect remains unclear. Therefore, we analyzed 981 lung adenocarcinomas to detect the potential correlation and combined effect of oncogenic mutations and histological subtype on prognosis. Analysis for oncogenic mutations included the direct sequencing of EGFR, KRAS, HER2, BRAF, PIK3CA, ALK, and RET for oncogenic mutations/rearrangements, and a rereview of the IASLC/ATS/ERS classification was undertaken. Eligible tumors included 13 atypical adenomatous hyperplasia/adenocarcinoma in situ, 20 minimally invasive adenocarcinomas, 901 invasive adenocarcinomas, 44 invasive mucinous adenocarcinomas, and three other variants. The invasive mucinous adenocarcinomas had a lower prevalence of EGFR mutations but a higher prevalence of KRAS, ALK, and HER2 mutations than invasive adenocarcinomas. Smoking, a solid predominant pattern, and a mucinous component were independently associated with fewer EGFR mutations. The ALK rearrangements were more frequently observed in tumors with a minor mucinous component, while the KRAS mutations were more prevalent in smokers. In addition, 503 patients with stage I-IIIA tumors were analyzed for overall survival (OS) and relapse-free survival. The stage and histological pattern were independent predictors of relapse-free survival, and the pathological stage was the only independent predictor for the OS. Although patients with the EGFR mutations had better OS than those without the mutations, no oncogenic mutation was an independent predictor of survival. Oncogenic mutations were associated with the novel IASLC/ATS/ERS classification, which facilitates a morphology-based mutational analysis strategy. The combination of these two classifications might not increase the prognostic ability, but it provides essential information for personalized treatment.
Clinical value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma (vol 8, pg 159, 2017)

Z. Guo,F. Yi,W. Yin,Y. Zhang,Q. Li,Y. Gu,Y. Xiao,B. Cao,L. Ma,L. Liang

DOI: https://doi.org/10.1111/1759-7714.12419

IF: 3.223

2018-01-01

Thoracic Cancer

Abstract:BackgroundWe explored correlations between the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification, epidermal growth factor receptor (EGFR) mutation status, and prognosis. MethodsData from 293 patients with lung adenocarcinoma were classified according to the new classification. Fisher's exact, (2), and log-rank tests and Cox regression analysis were used to analyze correlations between EGFR mutation status, lung cancer prognosis, and the new histologic subtype. Disease-free survival and progression-free survival (PFS) were estimated using the Kaplan-Meier method. Results Lepidic and non-solid adenocarcinomas showed significantly elevated EGFR mutation rates (79.0% and 65.8%, respectively; P< 0.05). EGFR mutation status was only associated with gender (P< 0.001). EGFR mutation-positive patients who received targeted therapy had better median PFS than those who received chemotherapy as first-line treatment (P< 0.001). The median PFS of patients with exon 19 and exon 21 mutations who received first-line targeted therapy were 12.5 and 9.5months, respectively (P=0.970). Patients with micropapillary predominant adenocarcinomas had the shortest disease-free survival (<18months) and PFS. Histologic subtype (P=0.036), treatment type (P=0.031), and EGFR mutation status (P=0.019) might be good prognostic factors for lung adenocarcinoma. ConclusionPatients with exon 19 mutations obtained greater benefits from targeted therapy. In the new classification, EGFR mutation rates are higher in lepidic cases and in cases without the solid subtype. The micropapillary subtype of adenocarcinoma has the worst prognosis, while the lepidic subtype has the best.
Prognostic Significance of the IASLC/ATS/ERS Classification in Chinese Patients—a Single Institution Retrospective Study of 292 Lung Adenocarcinoma

Jie Gu,Chunlai Lu,Jing Guo,Lingli Chen,Yiwei Chu,Yuan Ji,Di Ge

DOI: https://doi.org/10.1002/jso.23259

2012-01-01

Journal of Surgical Oncology

Abstract:Background A new classification of pulmonary adenocarcinoma has been recently proposed by the International Association for the Study of Lung Cancer, American Thoracic Society and European Respiratory Society (IASLC/ATS/ERS). This study was undertaken in an attempt to explore the clinical implication of this new classification in Chinese patients. Methods Two hundred ninety-two lung adenocarcinomas were reclassified strictly according to the IASLC/ATS/ERS classification by two pathologists, independently. KaplanMeier and Cox regression analyses were used to analyze the correlation between the new classification and patients' prognosis. Results We confirmed three groups with different outcomes. Both AIS and MIA had 100% 5-year disease-free survival rate and 100% 5-year overall survival rate. Lepidic, acinar, and papillary as well as variants of invasive adenocarcinoma had intermediate prognosis. Solid and micropapillary cases had poor prognosis (DFS: P<0.001, OS: P=0.002). After controlling the clinicopathological factors, the new classification was identified as an independent prognostic factor in patients' disease-free survival and overall survival. Conclusions We have demonstrated a valuable prognostic role of the new classification in Chinese patients. This new classification is valuable of screening out patients with high risk of recurrence to receive postoperative adjuvant therapy. J. Surg. Oncol. 2013;107:474480. (c) 2012 Wiley Periodicals, Inc.
Correlation of Survival and EGFR Mutation with Predominant Histologic Subtype According to the New Lung Adenocarcinoma Classification in Stage IB Patients

Yan Sun,Xinmin Yu,Xun Shi,Wei Hong,Jun Zhao,Lei Shi

DOI: https://doi.org/10.1186/1477-7819-12-148

2014-01-01

World Journal of Surgical Oncology

Abstract:Background A new lung adenocarcinoma classification proposed by the International Association for the Study of Lung Cancer, American Thoracic Society, and European Respiratory Society (IASLC/ATS/ERS) has recently been published. This study aimed to investigate the utility of the new histological classification for identifying the prognostic subtypes of adenocarcinomas in stage IB patients.Correlations between the classification and the presence of epidermal growth factor receptor (EGFR) mutation status was also studied. Methods One hundred and thirty-six patients with stage IB lung adenocarcinoma operated on in Zhejiang Cancer Hospital were identified between 2002 and 2011. Patients overall survival and disease-free survival were calculated using Kaplan-Meier and Cox regression analyses. EGFR mutations were detected using the amplification refractory mutation system. Results A total of 136 cases were included in current study, of which 38 were papillary predominant, 39 were acinar predominant, 22 were micropapillary predominant, 21 were lepidic predominant subtypes, 14 were solid predominant, and 2 were variants of invasive adenocarcinoma. Patients with micropapillary- and solid-predominant tumors had the lowest five-year disease-free survival (28.4 and 36.7%, respectively). Univariate and multivariate analysis showed that the micropapillary-predominant subtype was an independent predictor of disease-free survival ( P = 0.0041 and 0.048, respectively), but not overall survival ( P = 0.175 and 0.214, respectively). EGFR mutations were significantly associated with the micropapillary-predominant subtype patients ( P = 0.0026). The EGFR mutation frequency is lower in the solid-predominant subtype than other subtypes ( P = 0.0508). Conclusions The predominant subtype in the primary tumor was associated with prognosis in resected stage IB lung adenocarcinoma. The EGFR mutation frequency of micropapillary-predominant subtype is higher than other subtypes.
Identification of lung adenocarcinoma mutation status based on histologic subtype: Retrospective analysis of 269 patients

Fangliang Lu,Shaolei Li,Bin Dong,Shanyuan Zhang,Chao Lv,Yue Yang

DOI: https://doi.org/10.1111/1759-7714.12265

Abstract:Background: To evaluate differences in the clinical characteristics and molecular pathology of lung adenocarcinoma subtypes as defined by the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international histological classification. Methods: We retrospectively reviewed 269 patients with initial primary lung adenocarcinoma who had undergone complete resection at our department from August 2013 to December 2014, focusing on the new histologic subtype classification, clinical characteristics, and molecular pathology. Results: All specimens were invasive adenocarcinoma, and were lepidic (13.0%), papillary (19.7%), acinar (51.7%), solid (8.6%), micropapillary (1.1%) or mucinous predominant (5.9%). Epidermal growth factor receptor (EGFR) mutations were detected in 132 cases (60.3%). Female patients and non-smokers had higher EGFR mutation rates (P = 0.022 and 0.026, respectively). The lepidic, papillary, acinar, solid, micropapillary, and mucinous predominant patterns had EGFR mutation rates of 70.6%, 64.8%, 72.5%, 33.3%, 100%, and 5.9%, respectively. The exon mutation distribution differed according to serum carcinoembryonic antigen (CEA) levels (P = 0.018). v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations were detected in 20 cases (9.2%), and were frequently found in the mucinous and solid predominant subtypes. The serum CEA levels differed among the subtypes. Conclusions: In China, there are significant differences between lung adenocarcinoma histologic subtypes. The presence of well-differentiated components in lung adenocarcinoma indicates higher EGFR mutation rates; the presence of solid or mucinous components indicates higher KRAS mutation rates. Serum CEA levels are associated with histologic subtype and EGFR exon mutations.
Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study

Jianxin Shi,Xing Hua,Bin Zhu,Sarangan Ravichandran,Mingyi Wang,Cu Nguyen,Seth A. Brodie,Alessandro Palleschi,Marco Alloisio,Gianluca Pariscenti,Kristine Jones,Weiyin Zhou,Aaron J. Bouk,Joseph Boland,Belynda Hicks,Adam Risch,Hunter Bennett,Brian T. Luke,Lei Song,Jubao Duan,Pengyuan Liu,Takashi Kohno,Qingrong Chen,Daoud Meerzaman,Crystal Marconett,Ite Laird-Offringa,Ian Mills,Neil E. Caporaso,Mitchell H. Gail,Angela C. Pesatori,Dario Consonni,Pier Alberto Bertazzi,Stephen J. Chanock,Maria Teresa Landi

DOI: https://doi.org/10.1371/journal.pmed.1002162

2016-01-01

PLoS Medicine

Abstract:BACKGROUND:Lung adenocarcinoma (LUAD) is the most common histologic subtype of lung cancer and has a high risk of distant metastasis at every disease stage. We aimed to characterize the genomic landscape of LUAD and identify mutation signatures associated with tumor progression.METHODS AND FINDINGS:We performed an integrative genomic analysis, incorporating whole exome sequencing (WES), determination of DNA copy number and DNA methylation, and transcriptome sequencing for 101 LUAD samples from the Environment And Genetics in Lung cancer Etiology (EAGLE) study. We detected driver genes by testing whether the nonsynonymous mutation rate was significantly higher than the background mutation rate and replicated our findings in public datasets with 724 samples. We performed subclonality analysis for mutations based on mutant allele data and copy number alteration data. We also tested the association between mutation signatures and clinical outcomes, including distant metastasis, survival, and tumor grade. We identified and replicated two novel candidate driver genes, POU class 4 homeobox 2 (POU4F2) (mutated in 9 [8.9%] samples) and ZKSCAN1 (mutated in 6 [5.9%] samples), and characterized their major deleterious mutations. ZKSCAN1 was part of a mutually exclusive gene set that included the RTK/RAS/RAF pathway genes BRAF, EGFR, KRAS, MET, and NF1, indicating an important driver role for this gene. Moreover, we observed strong associations between methylation in specific genomic regions and somatic mutation patterns. In the tumor evolution analysis, four driver genes had a significantly lower fraction of subclonal mutations (FSM), including TP53 (p = 0.007), KEAP1 (p = 0.012), STK11 (p = 0.0076), and EGFR (p = 0.0078), suggesting a tumor initiation role for these genes. Subclonal mutations were significantly enriched in APOBEC-related signatures (p < 2.5×10-50). The total number of somatic mutations (p = 0.0039) and the fraction of transitions (p = 5.5×10-4) were associated with increased risk of distant metastasis. Our study's limitations include a small number of LUAD patients for subgroup analyses and a single-sample design for investigation of subclonality.CONCLUSIONS:These data provide a genomic characterization of LUAD pathogenesis and progression. The distinct clonal and subclonal mutation signatures suggest possible diverse carcinogenesis pathways for endogenous and exogenous exposures, and may serve as a foundation for more effective treatments for this lethal disease. LUAD's high heterogeneity emphasizes the need to further study this tumor type and to associate genomic findings with clinical outcomes.
Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification

Biao LIU,Shan-shan SHI,Xuan WANG,Yan XU,Xin-hua ZHANG,Bo YU,Zhen-feng LU,Jian-dong WANG,Xiao-jun ZHOU

DOI: https://doi.org/10.3760/cma.j.issn.0529-5807.2012.08.001

2012-01-01

Abstract:Objective To evaluate the relevance of molecular alterations and histopathological subtypes of lung adenocarcinoma according to 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Lung Adenocarcinoma Classification. Methods Mutations of epidermal growth factor receptor (EGFR) 18-21 exons ( E18-21 ),KRAS 12/13 codons and EML4-ALK fusion in 212 cases of lung adenocarcinoma which underwent complete tumor resection,were detected by immunohistochemistry,PCR-amplifying and gene sequencing.The relevance of the molecular alterations to histopathological subtypes based on the new classification and 2004 WHO classification were further characterized. Results Mutations of EGFR were observed in 49.6％ of lung adenocarcinomas,involving mainly E21 (52.4％,55/105 ) and E19 ( 36.2％,38/105). Mutations of KRAS were detected in 8％ cases of adenocarcinoma,involving mainly codon 12 (15/17). EML4-ALK fusions were found in 6.1％ of lung adenocarcinoma,the most common fusion mutation was type V1 ( E13; A20) (7/13),followed by type V3a/b ( E6a/b; A20) (4/13).Based on the new classification, 7/10 lepidic, 63.2％ (48/76) papillary, and 5/8 micropapillary predominant adenocarcinomas harbored EGFR mutations. EGFR mutations showed significant difference among different histological subtypes (P =0.008). KRAS mutations were most frequently found in invasive mucinous adenocarcinoma (1/2),followed by colloid predominant adenocarcinoma (3/7). There was siguificant difference of KRAS mutations among different histological subtypes ( P =0.003 ).EMLA-ALK fusions were most frequently found in the solid predominant with mucin production subtype ( 15.4％,6/39),followed by colloid predominant adenocarcinoma ( 1/7 ),and no significant difference of EMLA-ALK fusions was found among different histological subtypes ( P =0.181 ). Significant TTF-1 overexpression was observed in adenocarcinomas harbored EGFR mutations (P =0.008 ),and no or significantly lower level expression of TTF-1 was observed in adenocarcinomas harbored KRAS mutations (P =0.000). However,there was no association between TTF-1 expression and EML4-ALK fusions ( P =0.274 ). Based on the 2004 WHO classification,mutations of KRAS ( P =0.002 ) and EML4-ALK (P =0.000),rather than EGFR ( P =0.502),showed significant differences among different subtypes. According to both classification systems,the difference of " triple negative" adenocarcinomas was not significant among different subtypes ( P =0.684,P =0.449, respectively ). Conclusions The new classification, combined with TTF-1 immunomarker,can help to predict the molecular alterations of EGFR and KRAS genes,but can not indicate the EML4-ALK fusion in lung adenocarcinoma. Lepidic, papillary, and micropapillary predominant adenocarcinomas with TTF-1 expression are closely related to the presence of EGFR mutation,and invasive mucinous adenocarcinoma,while colloid predominant adenocarcinoma without TTF-1 expression is closely related to the presence of KRAS mutation.
Risk Stratification Model for Patients with Stage I Invasive Lung Adenocarcinoma Based on Clinical and Pathological Predictors.

Yiyang Wang,Difan Zheng,Jizhuang Luo,Jie Zhang,Cecilia Pompili,Hideki Ujiie,Natsumi Matsuura,Haiquan Chen,Feng Yao

DOI: https://doi.org/10.21037/tlcr-21-393

2021-01-01

Translational Lung Cancer Research

Abstract:BACKGROUND:The aim of this study was to propose a new kind of pathological classification and further establish a prognostic model for resected stage I invasive adenocarcinoma (IADC).METHODS:Clinicopathological data were collected from 2 hospitals. The new proposed pathological reclassification was defined according to certain subtype instead of a predominant one. Survival curves were plotted by Kaplan-Meier analysis. Cox regressions were analyzed for recurrence-free survival (RFS) and overall survival (OS), through which prognostic scores and stratification models were established. The comparison between risk models and the eighth edition of tumor, node, metastasis (TNM) classification was conducted through receiver operating characteristic curves (ROC), as identified by the area under the curve (AUC) and z test.RESULTS:In all, 1,196 patients were enrolled. At multivariable analysis, solid and micropapillary of the new pathological reclassification, along with stage IA3 and IB were independent predictors for poorer RFS. Stage IB and smoking status significantly indicated worse OS. After normalization and standardization of log-hazard ratio (HR), personalized scores were calculated and the risk stratifications with 3 risk groups were generated. Compared with TNM classification, the risk model of RFS showed advantage over early-recurrence prediction (1-year: 0.653 vs. 0.556, P=0.033; 3-year: 0.663 vs. 0.076, P=0.008). No marked difference was observed in long-term RFS or OS.CONCLUSIONS:Considering the harboring of certain patterns may be a new concept in adenocarcinoma classification. The risk stratification model based on this pathological classification and the eighth TNM classification showed remarkable superiority over TNM alone in predicting early recurrence of stage I adenocarcinoma. However, TNM classification remained valuable for long-term recurrence and survival prediction.
A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee

Andre L Moreira,Paolo S S Ocampo,Yuhe Xia,Hua Zhong,Prudence A Russell,Yuko Minami,Wendy A Cooper,Akihiko Yoshida,Lukas Bubendorf,Mauro Papotti,Giuseppe Pelosi,Fernando Lopez-Rios,Keiko Kunitoki,Dana Ferrari-Light,Lynette M Sholl,Mary Beth Beasley,Alain Borczuk,Johan Botling,Elisabeth Brambilla,Gang Chen,Teh-Ying Chou,Jin-Haeng Chung,Sanja Dacic,Deepali Jain,Fred R Hirsch,David Hwang,Sylvie Lantuejoul,Dongmei Lin,John W Longshore,Noriko Motoi,Masayuki Noguchi,Claudia Poleri,Natasha Rekhtman,Ming-Sound Tsao,Erik Thunnissen,William D Travis,Yasushi Yatabe,Anja C Roden,Jillian B Daigneault,Ignacio I Wistuba,Keith M Kerr,Harvey Pass,Andrew G Nicholson,Mari Mino-Kenudson,Andre L. Moreira,Paolo S.S. Ocampo,Prudence A. Russell,Wendy A. Cooper,Lynette M. Sholl,Fred R. Hirsch,John W. Longshore,William D. Travis,Anja C. Roden,Jillian B. Daigneault,Ignacio I. Wistuba,Keith M. Kerr,Andrew G. Nicholson

DOI: https://doi.org/10.1016/j.jtho.2020.06.001

IF: 20.121

2020-10-01

Journal of Thoracic Oncology

Abstract:INTRODUCTION: A grading system for pulmonary adenocarcinoma has not been established. The International Association for the Study of Lung Cancer pathology panel evaluated a set of histologic criteria associated with prognosis aimed at establishing a grading system for invasive pulmonary adenocarcinoma.METHODS: A multi-institutional study involving multiple cohorts of invasive pulmonary adenocarcinomas was conducted. A cohort of 284 stage I pulmonary adenocarcinomas was used as a training set to identify histologic features associated with patient outcomes (recurrence-free survival [RFS] and overall survival [OS]). Receiver operating characteristic curve analysis was used to select the best model, which was validated (n = 212) and tested (n = 300, including stage I-III) in independent cohorts. Reproducibility of the model was assessed using kappa statistics.RESULTS: The best model (area under the receiver operating characteristic curve [AUC] = 0.749 for RFS and 0.787 for OS) was composed of a combination of predominant plus high-grade histologic pattern with a cutoff of 20% for the latter. The model consists of the following: grade 1, lepidic predominant tumor; grade 2, acinar or papillary predominant tumor, both with no or less than 20% of high-grade patterns; and grade 3, any tumor with 20% or more of high-grade patterns (solid, micropapillary, or complex gland). Similar results were seen in the validation (AUC = 0.732 for RFS and 0.787 for OS) and test cohorts (AUC = 0.690 for RFS and 0.743 for OS), confirming the predictive value of the model. Interobserver reproducibility revealed good agreement (k = 0.617).CONCLUSIONS: A grading system based on the predominant and high-grade patterns is practical and prognostic for invasive pulmonary adenocarcinoma.

oncology,respiratory system
Histopathologic Pattern and Molecular Risk Stratification Are Associated with Prognosis in Patients with Stage IB Lung Adenocarcinoma

Weiran Liu,Chen,Qiang Zhang,Jiping Xie,Xinyi Wu,Zhenfa Zhang,Lin Shao,Haiwei Du,Songan Chen,Hirokazu Iso,Kakeru Hisakane,Dongsheng Yue,Bin Zhang

DOI: https://doi.org/10.21037/tlcr-24-506

2024-01-01

Translational Lung Cancer Research

Abstract:Background:The benefit of adjuvant therapy remains controversial in completely resected (R0) stage IB non-small cell lung cancer (NCLSC) patients. In this study, we aimed to explore potential prognostic factors in stage IB NSCLC patients. Methods:This study included 215 patients with R0 stage IB lung adenocarcinoma (LUAD) (tumor size: 3-4 cm). DNA sequencing was performed with surgical samples of 126 patients using a panel of 9 driver genes. The molecular risk stratification was assessed by a 14-gene quantitative polymerase chain reaction assay. Results:Among the 215 patients, 67.9% had micropapillary/solid (MIP/SOL)-predominant tumors. Epidermal growth factor receptor (EGFR) mutations were detected in 75 of 126 patients (59.5%). MIP/SOL tumors harbored less common EGFR mutations than the other histologic patterns (50.6% vs. 79.5%, P=0.003). Molecular risk stratification was successfully assessed in 99 patients, of whom 37.4%, 26.3%, and 36.4% were high, intermediate, and low risk, respectively. The MIP/SOL pattern was associated with shorter disease-free survival (DFS) [hazard ratio (HR) =2.16, 95% confidence interval: 1.28-3.67; P=0.01]. The molecular high-risk patients had shorter DFS than the low- (HR =2.93, P=0.01) and intermediate-risk patients (HR =2.35, P=0.06). The prognostic value of molecular risk stratification was also significant in the MIP/SOL subset (median DFS high-risk: 45 months, low and intermediate risk: not reached; P=0.03). Conclusions:Our study showed that both the MIP/SOL pattern and molecular high-risk category were adverse prognostic factors in stage IB NSCLC patients. Our results suggest that combining histologic classification and molecular risk stratification may help to identify the subset of patients with poor prognosis.
The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma

Raul Caso,Francisco Sanchez-Vega,Kay See Tan,Brooke Mastrogiacomo,Jian Zhou,Gregory D Jones,Bastien Nguyen,Nikolaus Schultz,James G Connolly,Whitney S Brandt,Matthew J Bott,Gaetano Rocco,Daniela Molena,James M Isbell,Yuan Liu,Marty W Mayo,Prasad S Adusumilli,William D Travis,David R Jones,Gregory D. Jones,James G. Connolly,Whitney S. Brandt,Matthew J. Bott,James M. Isbell,Marty W. Mayo,Prasad S. Adusumilli,William D. Travis,David R. Jones

DOI: https://doi.org/10.1016/j.jtho.2020.08.005

IF: 20.121

2020-12-01

Journal of Thoracic Oncology

Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Introduction</h3><p>The purpose of the study is to genomically characterize the biology and related therapeutic opportunities of prognostically important predominant histological subtypes in lung adenocarcinoma (LUAD).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>We identified 604 patients with stage I-III LUAD who underwent complete resection and targeted next-generation sequencing using the MSK-IMPACT platform. Tumors were classified according to predominant histologic subtype and grouped by architectural grade (lepidic [LEP], acinar or papillary [ACI/PAP], and micropapillary or solid [MIP/SOL]). Associations between clinicopathologic factors, genomic features, mutational signatures, and recurrence were examined within subtypes and, when appropriate, quantified using competing-risks regression, with adjustment for pathologic stage and extent of resection.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>MIP/SOL tumors had higher tumor mutational burden (<em>p</em><0.001), fraction of genome altered (<em>p</em>=0.001), copy number amplifications (<em>p</em>=0.021), rate of whole-genome doubling (<em>p</em>=0.008), and number of oncogenic pathways altered (<em>p</em><0.001), compared with LEP and ACI/PAP tumors. Across all tumors, mutational signatures attributed to APOBEC activity were associated with the highest risk of postresection recurrence: SBS2 (<em>p</em>=0.021) and SBS13 (<em>p</em>=0.005). Three oncogenic pathways (p53, Wnt, Myc) were altered with statistical significance in MIP/SOL tumors. Compared with LEP and ACI/PAP tumors, MIP/SOL tumors had a higher frequency of targetable <em>BRAF</em>-V600E mutations (<em>p</em>=0.046). Among ACI/PAP tumors, alterations in the cell cycle (<em>p</em><0.001) and PI3K (<em>p</em>=0.002) pathways were associated with recurrence; among MIP/SOL tumors, only PI3K alterations were (<em>p</em>=0.049).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>These results provide the first in-depth assessment of tumor genomic profiling of predominant LUAD histologic subtypes, their associations with recurrence, and their correlation with targetable driver alterations in patients with surgically resected LUAD.</p>

oncology,respiratory system
Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value

Laetitia Marisa,Aurélien de Reyniès,Alex Duval,Janick Selves,Marie Pierre Gaub,Laure Vescovo,Marie-Christine Etienne-Grimaldi,Renaud Schiappa,Dominique Guenot,Mira Ayadi,Sylvain Kirzin,Maurice Chazal,Jean-François Fléjou,Daniel Benchimol,Anne Berger,Arnaud Lagarde,Erwan Pencreach,Françoise Piard,Dominique Elias,Yann Parc,Sylviane Olschwang,Gérard Milano,Pierre Laurent-Puig,Valérie Boige

DOI: https://doi.org/10.1371/journal.pmed.1001453

2013-05-21

PLoS Medicine

Abstract:BACKGROUND: Colon cancer (CC) pathological staging fails to accurately predict recurrence, and to date, no gene expression signature has proven reliable for prognosis stratification in clinical practice, perhaps because CC is a heterogeneous disease. The aim of this study was to establish a comprehensive molecular classification of CC based on mRNA expression profile analyses.METHODS AND FINDINGS: Fresh-frozen primary tumor samples from a large multicenter cohort of 750 patients with stage I to IV CC who underwent surgery between 1987 and 2007 in seven centers were characterized for common DNA alterations, including BRAF, KRAS, and TP53 mutations, CpG island methylator phenotype, mismatch repair status, and chromosomal instability status, and were screened with whole genome and transcriptome arrays. 566 samples fulfilled RNA quality requirements. Unsupervised consensus hierarchical clustering applied to gene expression data from a discovery subset of 443 CC samples identified six molecular subtypes. These subtypes were associated with distinct clinicopathological characteristics, molecular alterations, specific enrichments of supervised gene expression signatures (stem cell phenotype-like, normal-like, serrated CC phenotype-like), and deregulated signaling pathways. Based on their main biological characteristics, we distinguished a deficient mismatch repair subtype, a KRAS mutant subtype, a cancer stem cell subtype, and three chromosomal instability subtypes, including one associated with down-regulated immune pathways, one with up-regulation of the Wnt pathway, and one displaying a normal-like gene expression profile. The classification was validated in the remaining 123 samples plus an independent set of 1,058 CC samples, including eight public datasets. Furthermore, prognosis was analyzed in the subset of stage II-III CC samples. The subtypes C4 and C6, but not the subtypes C1, C2, C3, and C5, were independently associated with shorter relapse-free survival, even after adjusting for age, sex, stage, and the emerging prognostic classifier Oncotype DX Colon Cancer Assay recurrence score (hazard ratio 1.5, 95% CI 1.1-2.1, p = 0.0097). However, a limitation of this study is that information on tumor grade and number of nodes examined was not available.CONCLUSIONS: We describe the first, to our knowledge, robust transcriptome-based classification of CC that improves the current disease stratification based on clinicopathological variables and common DNA markers. The biological relevance of these subtypes is illustrated by significant differences in prognosis. This analysis provides possibilities for improving prognostic models and therapeutic strategies. In conclusion, we report a new classification of CC into six molecular subtypes that arise through distinct biological pathways.

medicine, general & internal
[Analysis of the Effect of Different Pathological Subtypes to Prognosis in Stage I Pulmonary Adenocarcinoma].

Wei Jiang,Junjie Xi,Songtao Xu,Shaohua Lu,Qun Wang

DOI: https://doi.org/10.3760/cma.j.issn.0529-5815.2015.10.005

2015-01-01

Abstract:OBJECTIVETo analyze the prognostic value of the new classification (proposed by International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society) in stage I pulmonary adenocarcinoma.METHODSPathological slides of 328 cases of stage I pulmonary invasive adenocarcinoma were reviewed according to the new classification. The patients received operation in Department of Thoracic Surgery of Zhongshan Hospital affiliated to Fudan University from January 2005 to December 2009. There were 145 male and 183 female patients with an average age of (59 ± 10) years (ranging from 34 to 82 years). Clinical, pathological, and survival data were retrospectively analyzed. Kaplan-Meier method was used for analysis of survival, and Cox regression analysis was used for finding out prognostic factors.RESULTSFive-year progression-free survival rate and overall survival rate of lepidic-predominant subtype were both 100%. Five-year progression-free survival rate of patients with micropapillary component (49.3%) was significantly lower than that of patients without micropapillary component (75.4%, χ² = 8.154, P = 0.004). Regression analysis showed that tumor size is an independent prognostic factor of death (HR = 1.967, 95% CI: 1.507 to 2.567, P = 0.000) and recurrence (HR = 1.796, 95% CI: 1.469 to 2.198, P = 0.000). In subgroup analysis, the presence of solid component (HR = 1.985, 95% CI: 1.013 to 3.888, P = 0.046) and tumor size (HR = 1.941, 95% CI: 1.455 to 2.589, P = 0.000) were independent prognostic factors of recurrence for stage IB pulmonary adenocarcinoma.CONCLUSIONSThe new classification of adenocarcinoma is of prognostic value in stage I pulmonary adenocarcinoma. The presence of solid or micropapillary component impacts on survival. Detailed record of each component in tumor is necessary.
The Histologic Classifications of Lung Adenocarcinomas Are Discriminable by Unique Lineage Backgrounds

Haichuan Hu,Zhengliang Sun,Yuan Li,Yiliang Zhang,Hang Li,Yang Zhang,Yunjian Pan,Lei Shen,Rui Wang,Yihua Sun,Haiquan Chen

DOI: https://doi.org/10.1016/j.jtho.2016.07.016

IF: 20.121

2016-01-01

Journal of Thoracic Oncology

Abstract:Objectives: Lung adenocarcinomas are a heterogeneous set of diseases with distinct genetic and histologic characteristics. Besides the discovery of oncogenic mutations and introduction of the histologic classifications (2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society and 2015 WHO), increasing evidence has linked this intertumor heterogeneity to the lung lineage-specific pathways and lineage genes. Therefore, in this study, we assessed the gene expression of identified lung lineage genes to study their role in distinguishing lung adenocarcinoma diversities.Methods: A total of 278 surgically resected lung adenocarcinomas were included. Each case was evaluated for genetic mutations and histologic classification. Lineage genes associated with respiratory tract differentiation (NK2 homeobox 1 gene [NKX2-1], GATA protein binding 6 gene [GATA6], foxhead box J1 gene [FOXJ1], and SAM pointed domain containing ETS transcription factor gene [SPDEF]) and stem/basal-like status (inhibitor of DNA binding 2, HLH protein gene [ID2], POU class 5 homeobox 1 gene [POU5F1], SRY-box 2 gene [SOX2], and v-myc avian myelocytomatosis viral oncogene homolog gene [MYC]) were selected. mRNA expression of these genes in each tumor sample was assessed by quantitative real-time polymerase chain reaction and normalized to paired normal lung tissue.Results: Distinct lineage gene expressions were found on the basis of genetic and histologic diversities. Expression of NKX2-1, GATA6, FOXJ1, and POU5F1 exhibited a significant linear relationship across histologic subgroups that was independent of genetic mutation status. Expression levels of NKX2-1 and POU5F1 were also associated with EGFR mutation status, independent of histologic subtypes. Further analysis revealed that the overexpression of SPDEF defined longer relapse-free survivals, especially in stage I disease.Conclusions: For the first time, we showed the unique lineage backgrounds of different histologic subtypes and oncogenic mutations. Assessing this added parameter might be beneficial in discriminating intertumor heterogeneity, advancing target exploration, developing theranostic/prognostic biomarkers, and designing clinical trials. (C) 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
The prognostic value of histopathology in invasive lung adenocarcinoma: a comparative review of the main proposed grading systems

Stefano Lucà,Giuseppa Zannini,Floriana Morgillo,Carminia Maria Della Corte,Alfonso Fiorelli,Federica Zito Marino,Severo Campione,Giovanni Vicidomini,Gianluca Guggino,Andrea Ronchi,Marina Accardo,Renato Franco

DOI: https://doi.org/10.1080/14737140.2023.2179990

2023-02-22

Expert Review of Anticancer Therapy

Abstract:An accurate histological evaluation of invasive lung adenocarcinoma is essential for a correct clinical and pathological definition of the tumour. Different grading systems have been proposed to predict the prognosis of invasive lung adenocarcinoma. Invasive non mucinous lung adenocarcinoma is often morphologically heterogeneous, consisting of complex combinations of architectural patterns with different proportions. Several grading systems for non-mucinous lung adenocarcinoma have been proposed, being the main based on architectural differentiation and the predominant growth pattern. Herein we perform a thorough review of the literature using PubMed, Scopus and Web of Science and we highlight the peculiarities and the differences between the main grading systems and compare the data about their prognostic value. In addition, we carried out an evaluation of the proposed grading systems for less common histological variants of lung adenocarcinoma, such as fetal adenocarcinoma and invasive mucinous adenocarcinoma. The current IASLC grading system, based on the combined score of predominant growth pattern plus high-grade histological pattern, shows the stronger prognostic significance than the previous grading systems in invasive non mucinous lung adenocarcinoma.

oncology
P3.02-028 276 Cases of EGFR/ALK Gene Status and Predominant Histologic Subtype in Chinese Surgically Resected Lung Adenocarcinoma

Z. Huang,C. Xu,W. Wang,W. Zhuang,Zhengbo Song,Y. Chen,Gang Chen,M. Fang,T. Lv,You Song

DOI: https://doi.org/10.1016/j.jtho.2017.09.1558

IF: 20.121

2017-01-01

Journal of Thoracic Oncology

Abstract:A new lung adenocarcinoma classification proposed by WHO (2015) classification of tumors of the lung has recently been published. The aim of this study is to investigate the mutations of EGFR gene and ALK fusion gene in Chinese surgically resected lung adenocarcinomas. Reverse transcription polymerase chain reaction (RT-PCR) was used to detect the tissues in 276 patients of surgically resected lung adenocarcinomas with paraffin tissue EGFR gene mutation and ALK fusion gene. The total mutation rate in 276 patients of surgically resected lung adenocarcinomas was 54.71% (151/276). EGFR gene mutation rate were found in 19del (28.99%, 80/276), L858R (23.19%, 64/276), 20-ins (0.72%, 2/276), L861Q (0.72%, 2/276), G719X (1.09%, 3/276), S768I (0.36%, 1/276) and T790M (0.72%, 2/276) in surgically resected lung adenocarcinomas, including one case of G719X plus S768I, 19del plus T790M, L858R plus T790M, respectively. The total fusion positive rate in 207 patients of surgically resected lung adenocarcinomas was 5.80% (12/207). There were statistically significant (P<0.001, P<0.001, P=0.023, P<0.001 and P=0.030) in each subtype of lung adenocarcinoma of EGFR gene mutation, including lepidic predominant adenocarcinoma, acinar predominant adenocarcinoma, papillary predominant adenocarcinoma, solid predominant adenocarcinoma and invasive mucous adenocarcinoma, and there were not statistically significant (P>0.05) among other types. There were not statistically significant (P>0.05) among each types of lung adenocarcinoma of ALK fusion gene. Histologic subtyping was found to be associated with EGFR mutations. The EGFR mutation frequency of lepidic predominant, acinar predominant and papillary predominant subtypes was found to be more pronounced than that of other subtypes.
Why Do Pathological Stage IA Lung Adenocarcinomas Vary from Prognosis?: a Clinicopathologic Study of 176 Patients with Pathological Stage IA Lung Adenocarcinoma Based on the IASLC/ATS/ERS Classification.

Jie Zhang,Jie Wu,Qiang Tan,Lei Zhu,Wen Gao

DOI: https://doi.org/10.1097/jto.0b013e31829f09a7

IF: 20.121

2013-01-01

Journal of Thoracic Oncology

Abstract:BACKGROUND:Patients with pathological stage IA adenocarcinoma (AC) have a variable prognosis, even if treated in the same way. The postoperative treatment of pathological stage IA patients is also controversial.METHODS:We identified 176 patients with pathological stage IA AC who had undergone a lobectomy and mediastinal lymph node dissection at the Shanghai Chest Hospital, Shanghai, China, between 2000 and 2006. No patient had preoperative treatment. The histologic subtypes of all patients were classified according to the 2011 International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) international multidisciplinary lung AC classification. Patients' 5-year overall survival (OS) and 5-year disease-free survival (DFS) were calculated using Kaplan-Meier and Cox regression analyses.RESULTS:One hundred seventy-six patients with pathological stage IA AC had an 86.6% 5-year OS and 74.6% 5-year DFS. The 10 patients with micropapillary predominant subtype had the lowest 5-year DFS (40.0%).The 12 patients with solid predominant with mucin production subtype had the lowest 5-year OS (66.7%). Univariate and multivariate analysis showed that sex and prognositic groups of the IASLC/ATS/ERS histologic classification were significantly associated with 5-year DFS of pathological stage IA AC.CONCLUSION:Our study revealed that sex was an independent prognostic factor of pathological stage IA AC. The IASLC/ATS/ERS classification of lung AC identifies histologic categories with prognostic differences that could be helpful in clinical therapy.
Validation Study of New IASLC Histology Grading System in Stage I Non-Mucinous Adenocarcinoma Comparing With Minimally Invasive Adenocarcinoma

Wongi Woo,Yoon-Jin Cha,Bong Jun Kim,Duk Hwan Moon,Sungsoo Lee

DOI: https://doi.org/10.1016/j.cllc.2022.06.004

Abstract:Background: A new histologic grading system for pulmonary non-mucinous invasive adenocarcinoma was proposed by the International Association for the Study of Lung Cancer (IASLC). We evaluated its clinical impact on prognosis in stage I patients, including minimally invasive adenocarcinoma (MIA). Patients and methods: 919 patients underwent surgery for lung adenocarcinoma between 2012 and 2019. Stage I patients (n = 500) were retrospectively reviewed. They were divided into 4 categories: MIA and 3 new IASLC grades (grades 1-3). Cox proportional hazards analysis was performed to identify risk factors associated with recurrence and mortality. Furthermore, we compared the predictability of the IASLC grading system with different models that are based on the clinicopathologic characteristics (baseline model), TNM staging, and predominant histologic pattern. The area under the receiver operating characteristic curve (AUC) was calculated for comparison. Results: Recurrence-free survival (RFS) and overall survival (OS) were significantly stratified by the IASLC grading system in patients with stage I adenocarcinoma (P < .001 and P = .003, respectively). In multivariate analyses, IASLC grade 3 was a significant factor for RFS (hazard ratio [HR] 3.18, P < .001) and OS (HR 2.31, P = .013). The AUCs of the new IASLC model were 0.781 for recurrence and 0.770 for mortality, compared with those of the predominant pattern (0.769 for recurrence, 0.747 for death) and TNM staging (0.762 for recurrence, 0.747 for death). Conclusion: The IASLC grading system effectively predicted the prognosis of early-stage adenocarcinoma compared with previous models. The IASLC classification appears to improve the current system; therefore, precise pathologic examination for early-stage adenocarcinoma is warranted.
The Grading System for Lung Adenocarcinoma: Brief Review of its Prognostic Performance and Future Directions

Jose G. Mantilla,Andre L. Moreira

DOI: https://doi.org/10.1097/pap.0000000000000452

2024-04-26

Advances in Anatomic Pathology

Abstract:Histologic grading of tumors is associated with prognosis in many organs. In the lung, the most recent grading system proposed by International association for the Study of Lung Cancer (IASLC) and adopted by the World Health Organization (WHO) incorporates the predominant histologic pattern, as well as the presence of high-grade architectural patterns (solid, micropapillary, and complex glandular pattern) in proportions >20% of the tumor surface. This system has shown improved prognostic ability when compared with the prior grading system based on the predominant pattern alone, across different patient populations. Interobserver agreement is moderate to excellent, depending on the study. IASLC/WHO grading system has been shown to correlate with molecular alterations and PD-L1 expression in tumor cells. Recent studies interrogating gene expression has shown correlation with tumor grade and molecular alterations in the tumor microenvironment that can further stratify risk of recurrence. The use of machine learning algorithms to grade nonmucinous adenocarcinoma under this system has shown accuracy comparable to that of expert pulmonary pathologists. Future directions include evaluation of tumor grade in the context of adjuvant and neoadjuvant therapies, as well as the development of better prognostic indicators for mucinous adenocarcinoma.

pathology

The influence of beam energy on the outcome of postoperative radiotherapy in head and neck cancer patients: secondary analysis of RTOG 85-03.

Comprehensive Investigation of Mutational Features of Various Lung Adenocarcinoma Histological Subtypes among Chinese Patients.

Oncogenic Mutations Are Associated with Histological Subtypes but Do Not Have an Independent Prognostic Value in Lung Adenocarcinoma

Clinical value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma (vol 8, pg 159, 2017)

Prognostic Significance of the IASLC/ATS/ERS Classification in Chinese Patients—a Single Institution Retrospective Study of 292 Lung Adenocarcinoma

Correlation of Survival and EGFR Mutation with Predominant Histologic Subtype According to the New Lung Adenocarcinoma Classification in Stage IB Patients

Identification of lung adenocarcinoma mutation status based on histologic subtype: Retrospective analysis of 269 patients

Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study

Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification

Risk Stratification Model for Patients with Stage I Invasive Lung Adenocarcinoma Based on Clinical and Pathological Predictors.

A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee

Histopathologic Pattern and Molecular Risk Stratification Are Associated with Prognosis in Patients with Stage IB Lung Adenocarcinoma

The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma

Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value

[Analysis of the Effect of Different Pathological Subtypes to Prognosis in Stage I Pulmonary Adenocarcinoma].

The Histologic Classifications of Lung Adenocarcinomas Are Discriminable by Unique Lineage Backgrounds

The prognostic value of histopathology in invasive lung adenocarcinoma: a comparative review of the main proposed grading systems

P3.02-028 276 Cases of EGFR/ALK Gene Status and Predominant Histologic Subtype in Chinese Surgically Resected Lung Adenocarcinoma

Why Do Pathological Stage IA Lung Adenocarcinomas Vary from Prognosis?: a Clinicopathologic Study of 176 Patients with Pathological Stage IA Lung Adenocarcinoma Based on the IASLC/ATS/ERS Classification.

Validation Study of New IASLC Histology Grading System in Stage I Non-Mucinous Adenocarcinoma Comparing With Minimally Invasive Adenocarcinoma

The Grading System for Lung Adenocarcinoma: Brief Review of its Prognostic Performance and Future Directions